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regulation of cholesterol metabolism in Imai rats with sponta-Molecular mechanisms of altered cholesterol metabolism in
neous FGS, which closely resembles FGS in humans.rats with spontaneous focal glomerulosclerosis.
Background. Imai rats exhibit spontaneous focal glomerulo-
sclerosis (FGS), which is marked by heavy proteinuria, severe
hyperlipidemia, and progressive renal insufficiency beginning
Imai rats were originally derived from the mating of aat 8 to 10 weeks of age. In an earlier study, we reported severe
male Sprague-Dawley rat that exhibited spontaneous re-skeletal muscle and adipose tissue lipoprotein lipase, and very
low-density lipoprotein (VLDL) receptor deficiencies, which nal disease and hyperlipidemia while consuming a low-fat
account for elevated plasma VLDL and triglycerides in Imai basal diet [1]. Male Imai rats develop a progressive focal
rats at 34 weeks of age. In this study, we investigated key factors glomerulosclerosis (FGS), which presents with mild pro-involved in cholesterol metabolism.
teinuria at 5 to 6 weeks of age progressing to frank protein-Methods. Male Imai and Sprague-Dawley control rats were
uria and hyperlipidemia by 8 to 10 weeks of age, and sig-fed a regular rat chow and observed from age 8 through 34
weeks. Hepatic 3-hydroxy-3 methylglutaryl coenzyme A (HMG- nificant renal insufficiency by 30 to 40 weeks of age [2].
CoA) reductase, cholesterol 7-hydroxylase, low-density lipo- The severity of the disease is considerably less and the
protein (LDL) receptor and acyl Co A:cholesterol acyltransferase
onset of the disease is significantly delayed in female ani-(ACAT) were measured by Western blot and plasma lecithin:cho-
mals [1]. The histologic and biochemical features of FGSlesterol acyltransferase (LCAT) protein was measured by en-
zyme-linked immunosorbent assay (ELISA). in the Imai rats closely resemble those of progressive
Results. At 34 weeks of age, the Imai rats showed severe FGS in humans [2, 3].
proteinuria, hypoalbuminemia, 60% reduction in glomerular Severe nephrotic proteinuria in the Imai rats is accom-filtration rate (GFR), elevated plasma total and LDL choles-
panied by marked elevation of plasma cholesterol, tri-terol and LDL/high-density lipoprotein (HDL) ratio. Imai rats
showed a twofold elevation of hepatic HMG-CoA reductase, glycerides, low-density lipoproteins (LDL) and very low-
the rate-limiting step in cholesterol biosynthesis, but no signifi- density lipoproteins (VLDL) and phospholipid concen-
cant change in cholesterol 7-hydroxylase, the rate-limiting trations [1, 2]. In a recent study, we found marked down-
enzyme in cholesterol catabolism to bile acids. This was accom-
regulations of lipoprotein lipase and VLDL receptor inpanied by and largely due to a threefold down-regulation of
adipose tissue and skeletal muscle of 34-week-old Imaihepatic LDL receptor, which limits hepatic uptake of LDL;
and a threefold up-regulation of hepatic ACAT (P  0.01), rats with severe nephrotic proteinuria and moderate re-
which augments esterification of hepatocyte free cholesterol, nal insufficiency [4]. These findings helped to elucidate
thus, limiting cholesterol-mediated feedback regulation of cho-
the molecular mechanism of hypertriglyceridemia andlesterol synthesis and catabolism. Moreover, plasma LCAT
elevation of plasma VLDL in this model. The observedconcentration was severely depressed (by fourfold) in Imai
rats. This abnormality can impair HDL-mediated cholesterol down-regulations of lipoprotein lipase and VLDL recep-
transport from extrahepatic tissues to the liver. tor in 34-week-old Imai rats exhibiting severe nephrotic
Conclusion. The study revealed marked abnormalities of syndrome and moderate renal insufficiency paralleledthe key proteins involved in regulation of hepatic cholesterol
the findings of our earlier studies in rats with puromycin-metabolism. These abnormalities can account for severe dys-
induced nephrotic syndrome [5, 6] and those with chronic
renal insufficiency induced by 5/6 nephrectomy [7–9].
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The present study was designed to discern the molecu-emia, HMG-CoA reductase, cholesterol-7-hydroxylase, LDL recep-
tor, LCAT, ACAT, bile acids. lar basis of hypercholesterolemia, elevation of plasma
LDL and LDL to high-density lipoprotein (HDL) cho-
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rate-limiting step in cholesterol synthesis), cholesterol by a kit purchased from Wako Pure Chemical Industries,
Tokyo, Japan.7-hydroxylase (the rate-limiting step in cholesterol ca-
Creatinine clearance was calculated from urinary andtabolism to bile acids), LDL receptor (the principal path-
plasma creatinine values using the standard formula.way of cholesterol clearance) and acyl CoA:cholesterol
Plasma HDL, LDL, and VLDL levels were determinedacyltransferase (ACAT) (the main enzyme responsible
by ultracentrifugation method as described by Lasserfor intracellular esterification of cholesterol) in male
et al [10].Imai rats with FGS and age-matched male Sprague-Daw-
ley control rats. In addition, plasma immunodetectable
HMG-CoA reductase protein determinationlecithin:cholesterol acyltransferase (LCAT), which is the
Frozen rat liver tissue was homogenized in 1 mL ofmain enzyme responsible for esterification of cholesterol
20 mmol/L Tris-HCl (pH 7.5) buffer containing 2 mmol/Lin the plasma and maturation of HDL was measured.
MgCl2, 0.2 mol/L sucrose, 5 mmol/L phenylmethylsulfo-We studied the Imai rats at 34 weeks of age at which
nyl fluoride, 5 g/mL leupeptin, 10 g/mL aprotinin, andpoint severe nephrotic syndrome and moderate renal
3 g/mL pepstatin A. The crude extract was centrifugedinsufficiency were present. It is of note that earlier studies
at 12,000  g at 4C for 10 minutes to remove tissuefrom our group and other investigators had explored the
debris. The supernatant was processed for determinationeffects of nephrotic syndrome and chronic renal insuffi-
of HMG-CoA reductase. Protein concentration of the su-ciency separately. However, little is known about the
pernatant was determined by a bicinchoninic acid (BCA)effects of the combination of the two conditions, which
protein assay kit (Pierce, Inc., Rockford, IL, USA). HMG-frequently occurs in advanced stages of FGS and many
CoA reductase protein abundance in the liver extractother glomerulopathies in animals and humans. Investi-
was quantified by Western blot analysis as described bygation of the Imai rats at 34 weeks of age afforded the
Ness, Chambers, and Lopez [11]. Briefly, aliquots con-opportunity to explore this issue.
taining 100 g proteins were fractionated on 4% to 20%
Tris-glycine gel (Novex, Inc., San Diego, CA, USA) at
METHODS 120 V for 2 hours. After electrophoresis, proteins were
transferred to Hybond-ECL membrane (Amersham LifeAnimals
Science, Inc., Arlington Heights, IL, USA). The mem-Imai hyperlipidemic rats (Biological Research Labo-
brane was incubated for 1 hour in blocking buffer [1ratories, Central Research Division of Takeda Chemical
Tris-buffered saline (TBS), 0.1% Tween-20 and 7% non-
Industries, Osaka, Japan) were bred in the animal facility
fat milk] and then overnight in the same buffer con-
of Saga Medical School (Saga, Japan). Six male Imai taining 1:7500 polyclonal anti-HMG-CoA reductase an-
rats and six male Sprague-Dawley control rats were mon- tibody (generously provided by Professor G.C. Ness,
itored for 34 weeks. They were fed a regular rat chow Department of Biochemistry and Molecular Biology,
(containing 24.8% protein, and 0.08% cholesterol) and University of South Florida, Tampa, Florida). Mem-
housed in a climate-controlled space with 12-hour light, brane was washed four times for 10 minutes in 1 TBS,
12-hour dark cycles. All animals were allowed access to 0.1% Tween-20 prior to a 2-hour incubation in blocking
food and water ad libitum. Arterial pressure was mea- buffer plus diluted (1:10,000) horseradish peroxidase–
sured by a tail plethysmograph (Harvard Apparatus, Cam- linked antirabbit immunoglobulin G (IgG) (Amersham
bridge, MA, USA). A 24-hour urine collection was ob- Life Science, Inc.). The washes were repeated before
tained for determinations of urinary protein and creati- the membranes were developed with chemiluminescent
nine excretion using metabolic cages. At the conclusion agents (ECL; Amersham Life Science Inc.) and sub-
of each observation period, animals were anesthetized jected to autoluminography for 3 minutes.
with intraperitoneal injections of pentobarbital (50 mg/kg)
and euthanized by exsanguination using cardiac punc- Determination of cholesterol 7-hydroxylase protein
ture. Liver was harvested and frozen in liquid nitrogen Cholesterol 7-hydroxylase protein abundance in the
immediately and stored at 70C until processed. In liver tissue preparation was determined by Western blot
addition, plasma was separated and used for measure- analysis using a rabbit antirat cholesterol 7-hydroxylase
ments of lipids, creatinine and albumin concentrations, antibody as described in our earlier studies [12]. The
as well as LCAT protein abundance. antibody employed in this assay was generously provided
by Professor John Y.L. Chiang (Northeastern Ohio Uni-
Routine biochemical determinations versity College of Medicine, Rootstown, OH).
Serum total cholesterol, triglyceride, creatinine, and al-
Determination of LDL receptor proteinbumin concentrations were measured by a synchro CX3
autoanalyzer (Beckman Instruments, Inc., Fullerton, CA, Hepatic LDL receptor protein abundance was deter-
mined in the plasma membrane preparation by WesternUSA). Urinary protein concentration was determined
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Table 1. Serum concentrations of total triglycerides, veryblot analysis using a mouse antibovine LDL receptor
low-density lipoproteins triglycerides (VLDL-TG), albumin,
antibody (Cortex Biochemi, Inc., Davis, CA, USA) as and creatinine, creatinine clearance, urinary protein excretion
and systolic blood pressure in normal Sprague-Dawley control ratsdescribed in our previous study [13].
and 34-week-old Imai rats with focal glomerulosclerosis (FGS)
Determination of ACAT-2 protein CTL FGS
(N  6) (N  6) P valuesHepatic ACAT-2 protein abundance was quantified
Triglyceride mg/dL 73.110.2 218.115.2 0.005by Western analysis using a polyclonal antibody against
VLDL-TG mg/dL 63.010.2 194.416.3 0.005ACAT-2 as described in our recent study [14]. The anti-
Albumin g/dL 3.700.1 2.800.1 0.005
body employed in these experiments was a generous Creatinine mg/dL 0.540.29 1.050.14 0.001
Creatinine clearancegift from Professor Lawrence L. Rudel, Department of
mL/min · g kidney weight 0.540.03 0.200.04 0.001Biochemistry and Comparative Medicine, Wake Forest
Urinary protein mg/24 hours 35.25.5 467.027.7 0.001
University, Winston-Salem, North Carolina. Blood pressure mm Hg 116.75.9 187.512.6 0.001
Values are meanSEM.Determination of plasma LCAT protein
Plasma LCAT protein concentration was measured in
triplicate by enzyme-linked immunosorbent assay (ELISA) in VLDL triglyceride concentrations. Plasma free choles-
method using rabbit antihuman LCAT antibody as de- terol was significantly increased, whereas liver tissue cho-
scribed by Wang et al [15]. This antibody was generously lesterol concentration was significantly reduced in the
supplied by Professor John S. Parks, Wake Forest Uni- Imai rats when compared with the control group.
versity, Winston-Salem, North Carolina. Briefly, 10 uL
of plasma were diluted in binding buffer (1  TBS, Hepatic HMG-CoA reductase data
0.05% NaN3, 200 uL final volume) and incubated at 4C Data are depicted in Figure 1. The FGS group showed
overnight in microtiter plates. The wells were washed 3 a twofold elevation of HMG-CoA reductase protein abun-
times with washing buffer (1  TBS and 0.05% Tween- dance in the liver tissue when compared with the normal
20) and blocked for 3 hours at room temperature with control group. A significant direct correlation was found
blocking buffer [0.5% bovine serum albumin (BSA) and between hepatic HMG-CoA reductase and serum total
0.05% Tween-20 in 1  TBA] and washed. A 1:2000 cholesterol concentration (r  0. 9, P  0.001).
dilution of rabbit antihuman LCAT antibody in blocking
buffer were added into the well and incubated at room Hepatic cholesterol 7-hydroxylase data
temperature for 3 hours. The plates were washed and incu- Results are illustrated in Figure 2. Despite severe hy-
bated with 1:2000 antirabbit IgG conjugated with horserad- percholesterolemia, hepatic tissue cholesterol 7-hydrox-
ish peroxidase (Sigma Chemical, Inc.) and developed ylase abundance in the FGS group was virtually identical
with 1-stepTM Turbo-TMB-ELISA kit (Pierce Inc.) and to that of normocholesterolemic control animals. How-
read at 450 nm after color developed. Purified human
ever, HMG-CoA reductase to cholesterol 7-hydroxy-
plasma LCAT was used as standard for the assay.
lase ratio (which reflects the balance between hepatic
cholesterol biosynthesis and catabolism) was markedlyData analysis
increased in the FGS group as compared to that in theStudent t test and regression analysis were used in
control group.statistical analysis of the data, which are presented as
mean  SE. P values less than 0.05 were considered Hepatic LDL receptor protein data
significant.
Data are given in Figure 3. The FGS group showed an
approximately 2.5-fold reduction in hepatic tissue LDL
RESULTS receptor protein abundance as compared to the normal
control group. A significant inverse correlation was foundGeneral data
between liver tissue LDL receptor protein abundanceData are shown in Table 1 and Figures 1 and 3 to 5.
and serum LDL cholesterol concentration in the studyThe FGS group exhibited severe proteinuria, hypoalbu-
animals (r  0. 7, P  0.05).minemia, arterial hypertension, elevated serum creatinine
concentration, and reduced creatinine clearance. Com-
Hepatic ACAT-2 resultspared with the control group, the FGS animals showed
Data are shown in Figure 4. Liver-specific ACAT-2a fivefold elevation of serum total cholesterol, a 15-fold
protein abundance was nearly 2.5-fold higher in the FGSincreased in LDL cholesterol, a threefold rise in VLDL
group as compared with the normal control group. He-cholesterol, and a fivefold increase in LDL cholesterol/
patic ACAT-2 abundance was inversely related to liverHDL cholesterol ratio. This was coupled with a threefold
elevation of serum total triglycerides and a threefold rise free cholesterol (r  0.74, P  0.01) concentration.
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Fig. 1. Representative Western blot and group data depicting hepatic
tissue microsomal 3-hydroxy-3 methyglutaryl coenzyme A (HMG-CoA)
reductase protein abundance and plasma cholesterol concentration in the Fig. 2. Representative Western blot and group data depicting hepatic
34-week-old Imai rats with focal glomerulosclerosis (FGS) and the age- tissue microsomal cholesterol 7-hydroxylase (CH-7) protein abun-
matched normal control group. N  6 in each group. *P  0.01. dance and 3-hydroxy-3 methyglutaryl coenzyme A (HMG-CoA) reduc-
tase-to-cholesterol 7-hydroxylase ratio in the 34-week-old Imai rats
with focal glomerulosclerosis (FGS) and the age-matched normal con-
trol group. N  6 in each group. No significant difference was found.
Plasma LCAT data
Results are depicted in Figure 5. Plasma LCAT protein
concentration was approximately fourfold lower in the ever, the molecular mechanisms responsible for these
FGS group than that in the normal control group. Plasma phenomena were not known.
LCAT protein concentration was inversely related to Hypercholesterolemia in our nephrotic rats with spon-
taneous FGS was accompanied by an approximately two-serum LDL cholesterol to HDL cholesterol concentra-
fold increase in the liver tissue abundance of HMG-CoAtion ratio (r  0.72, P  0.05) and serum free choles-
reductase. The endoplasmic reticulum-bound enzyme,terol concentration (r  0.84, P  0.01).
HMG-CoA reductase is the rate-limiting factor in cho-
lesterol biosynthesis. Although this enzyme is expressed
DISCUSSION in all tissues, it is most abundantly expressed in the liver,
Severe nephrotic proteinuria in our Imai rats with FGS which plays a critical role in regulation of plasma choles-
was accompanied by marked elevation of serum total terol level [18]. Thus, marked up-regulation of hepatic
cholesterol and LDL cholesterol concentrations. Earlier HMG-CoA reductase in the FGS group can contribute
studies have pointed to increased LDL synthesis [16] and to hypercholesterolemia in these animals. This supposi-
depressed LDL clearance [17] as the cause of increased tion is supported by the observed correlation between
hepatic HMG-CoA reductase and serum cholesterol inplasma LDL cholesterol in nephrotic syndrome. How-
Vaziri et al: Mechanism of hypercholesterolemia in FGS1760
Fig. 3. Representative Western blot and group data depicting hepatic
tissue plasma membrane low-density lipoprotein (LDL) receptor pro-
tein abundance and plasma LDL concentration in the 34-week-old Imai
rats with focal glomerulosclerosis (FGS) and the age-matched normal
control group. N  6 in each group. *P  0.01.
the study animals. In an earlier study, we found up-regula-
tion of hepatic HMG-CoA reductase mRNA abundance
Fig. 4. Representative Western blot and group data depicting hepaticand enzymatic activity in rats with puromycin-induced
tissue acyl CoA:cholesterol acyltransferase (ACAT-2) protein abun-nephrotic syndrome [19]. The present study revealed up- dance, liver-free cholesterol and plasma very low-density lipoprotein
regulation of immunodetectable HMG-CoA reductase (VLDL) concentration in the 34-week-old Imai rats with focal glomeru-
losclerosis (FGS) and the age-matched normal control group. N  6 inprotein in spontaneously occurring nephrotic syndrome
each group. *P  0.01.caused by a glomerulopathy, which closely resembles
FGS in humans.
Despite severe hypercholesterolemia, hepatic tissue
cholesterol 7-hydroxylase protein abundance in our of cholesterol biosynthesis [18], coupled with a lack of
rise in cholesterol 7-hydroxylase, which is the determi-FGS animals was virtually identical to that of the normo-
cholesterolemic control rats. Cholesterol 7-hydroxylase nant of cholesterol catabolism, can support the induction
and maintenance of hypercholesterolemia in the FGSis a unique cytochrome P450 enzyme, which is the first
and the rate-controlling step in cholesterol conversion animals. The failure of the nephrotic liver to raise choles-
terol 7-hydroxylase expression in rats with spontaneousto bile acids. Consequently, this enzyme plays a critical
role in cholesterol catabolism. The observed up-regula- FGS is consistent with our earlier studies of animals with
puromycin-induced proteinuria [12].tion of HMG-CoA reductase, which is the determinant
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receptor deficiency observed in our nephrotic rats with
FGS could have contributed to the associated elevation
of LDL and total cholesterol concentrations. This view-
point is supported by the strong inverse correlation be-
tween hepatic LDL receptor and plasma total and LDL
cholesterol levels founds in the study animals. This phe-
nomenon provides the molecular basis for the previously
reported impairment of LDL clearance in nephrotic syn-
drome [17]. Down-regulation of hepatic LDL receptor
protein abundance found in the nephrotic rats with spon-
taneous FGS is consistent with the results of our earlier
study in rats with puromycin-induced nephrotic syn-
drome [13], thus, pointing to the relevance of the findings
to nephrotic syndrome regardless of the underlying cause.
Nephrotic proteinuria in our 34-week-old Imai rats
was accompanied by moderate renal insufficiency. This
may raise the question as to the possible contribution of
renal insufficiency in the pathogenesis of the observed
dysregulation of the above cholesterol regulatory pro-
teins in the liver of our FGS rats. In an earlier study
of rats with chronic renal insufficiency induced by 5/6
nephrectomy, we found no significant change in hepatic
expression of either HMG-CoA reductase, cholesterol
7-hydroxylase, or LDL receptor [21]. The latter study
tends to exclude the possible role of renal insufficiency
in the pathogenesis of the above abnormalities.
Liver tissue ACAT-2 protein abundance was nearly
2.5-fold greater in our Imai rats with FGS than that found
in the control group. ACAT is a membrane-associated
enzyme, which is primarily localized in the endoplasmic
reticulum. ACAT catalyzes intracellular esterification of
cholesterol and formation of cholesterol ester in nearly
all mammalian cells [22]. Two isoforms of ACAT have,
thus far, been identified. These include ACAT-1, which
is expressed in most tissues, and ACAT-2, which is pri-
marily expressed in the liver and intestine [23–26]. Esteri-
fication of free cholesterol by ACAT has been shown
to enhance production and secretion of VLDL by the
liver [27–29]. Thus, up-regulation of hepatic ACAT-2
in our rats with spontaneous FGS may contribute toFig. 5. Plasma lecithin:cholesterol acyltransferase (LCAT) protein
concentration plasma-free cholesterol and high-density lipoprotein elevation of plasma VLDL in these animals. Expression
(LDL) to high-density lipoprotein (HDL) cholesterol ratio in the
of HGM-CoA reductase is inhibited, while that of choles-34-week-old Imai rats with focal glomerulosclerosis (FGS) and the
terol 7-hydroxylase is up-regulated by free cholesterolage-matched normal control group. N  6 animals in each group.
*P  0.01. in the hepatocyte [30, 31]. Thus, the observed up-regula-
tion of HGM-CoA reductase and the lack of rise in choles-
terol 7-hydroxylase seen in the FGS rats may be, in part,
due to up-regulation of ACAT-2, which helps to lowerElevation of serum total cholesterol and LDL choles-
cellular free cholesterol concentration by catalyzing theterol concentration in our FGS rats was associated with
formation of cholesterol ester. This is compounded byan approximately 2.5-fold reduction in hepatic LDL re-
LDL receptor deficiency, which limits the influx of cho-ceptor protein abundance. LDL receptor-mediated he-
lesterol into the hepatocyte.patic uptake of LDL represents the predominant path-
In a series of recent studies, we have demonstratedway of clearance of plasma cholesterol. In fact, hereditary
marked up-regulation of ACAT-2 in rats with puro-LDL receptor deficiency results in severe hypercholes-
mycin-induced nephrotic syndrome [14] and rats withterolemia and premature atherosclerotic cardiovascular
disease [20]. It is, therefore, intuitive that acquired LDL chronic renal insufficiency induced by 5/6 nephrectomy
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[32]. Accordingly, both severe nephrotic proteinuria and Comparative analysis of data obtained in our earlier
studies of rats with either nephrotic syndrome or chronicmoderate renal insufficiency appear to have contributed
to up-regulation of ACAT-2 in our Imai rats with sponta- renal insufficiency alone with those of the 34-week old
Imai rats exhibiting both conditions revealed predomi-neous FGS.
Plasma LCAT protein concentration in our FGS rats nant effect of nephrotic syndrome on expression of the
main cholesterol-regulatory enzymes and receptors. How-was approximately fourfold lower than that found in the
normal control group. LCAT is a 63 kD glycoprotein ever, our earlier studies of the enzymes and receptors
involved in metabolism of triglyceride-rich lipoproteinsenzyme that is made and secreted in the plasma by the
liver. In the presence of cofactor, ApoA-I, the enzyme in this model revealed additive effects of nephrotic syn-
drome and renal insufficiency on plasma lipids and tissuecatalyses hydrolysis of a Sn2 fatty acid from phospholipid
and transesterification of fatty acid to the 3-hydroxyl lipoprotein lipase and VLDL receptor expressions [4].
group of cholesterol to form cholesterol ester [33]. HDL
is the main carrier of LCAT in the plasma and the pre-
CONCLUSION
ferred macromolecular platform for the LCAT reactions.
Imai rats with spontaneous FGS exhibited marked up-LCAT is essential for maturation of cholesterol-poor
regulation of hepatic HMG-CoA reductase and ACAT-2HDL-3 or nascent HDL to the cardioprotective choles-
coupled with severe acquired LDL receptor and LCATterol ester-rich HDL-2. The role of LCAT in this process
deficiencies. Dysregulation of these key cholesterol regu-involves generation of a chemical concentration gradient
latory factors can account for the profound alterationsfor optimal efflux of free cholesterol from the peripheral
of cholesterol metabolism in advanced FGS presentingcells into the HDL particle through rapid conversion of
with a combination of severe nephrotic proteinuria andfree cholesterol to esterified cholesterol. Thus, LCAT
moderate renal insufficiency.plays an important role in HDL-mediated retrieval of
surplus cholesterol from the peripheral cells for disposal Reprint requests to Nosratola D.Vaziri, M.D., M.A.C.P., UCI Medi-
cal Center, Division of Nephrology and Hypertension, 101 The Cityin the liver, a phenomenon commonly referred to as
Drive, Bldg 53, Room 125, Rt 81, Orange, CA 92868.reverse cholesterol transport.
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